Altamira Therapeutics Ltd

Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through the following geographical segments: United States, Switzerland, Europe, and Australia. Its product pipeline includes AM-125, AM-201, AM301, Sonsuvi, and Keyzilen. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.

Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through the Switzerland and Australia geographical segments. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.

Hamilton, Bermuda, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (NASDAQ: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that its licensee and distribution partner Nuance Pharma has launched its Bentrio nasal spray in Hong Kong.

Altamira Therapeutics Announces Launch of Bentrio in Hong Kong by its Partner Nuance Pharma

• Animal study shows effective protection of mitochondria from oxidative damage and reduced plaque vulnerability in advanced atherosclerosis following treatment with SOD2 mRNA nanoparticles based on Altamira's SemaPhore™ technology • Data presented at American Heart Association Annual Scientific Sessions Chicago 2022, earlier this month HAMILTON, BERMUDA / ACCESSWIRE / November 22, 2022 / Altamira Therapeutics ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced the presentation of animal data generated by an atherosclerosis research group at the University of Michigan School of Medicine (Ann Arbor, MI) showing effective delivery of mRNA, and protective effects in arteries, with its SemaPhore™ delivery technology. The data was presented at the prestigious American Heart Association Annual Scientific Sessions Chicago 2022, earlier this month.

In Vivo Data Presented at AHA Conference Demonstrates Altamira Therapeutics' SemaPhore mRNA Delivery Platform to Effectively Help Preserve Atherosclerotic Plaque Stability

Hamilton, Bermuda, Nov. 10, 2022 (GLOBE NEWSWIRE) -- • TIDES Europe Event will be held on November 16-18, 2022, in Vienna, Austria • Company Chief Development Officer, Covadonga Pañeda, Ph.D., to present on the advantages of Altamira's OligoPhoreTM / SemaPhoreTM RNA delivery technology • Dr. Pañeda to discuss the Company's two proprietary RNA programs, AM-401 and AM-411

Altamira Therapeutics to Participate at TIDES Europe Oligonucleotide and Peptide Therapeutics Hybrid Event

Hamilton, Bermuda, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (NASDAQ: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs today announced that it has regained compliance with the Nasdaq listing requirements. On November 08, 2022 the Company received a letter from Nasdaq stating that because the Company's shares had a closing bid price at or above $1.00 per share for a minimum of ten (10) consecutive business days, the Company's stock had regained compliance with the Minimum Bid Price Requirement for continued listing on Nasdaq, and that the matter is now closed.

Altamira Therapeutics Regains Listing Compliance with NASDAQ Minimum Bid Requirement

HAMILTON, BERMUDA, Nov. 08, 2022 (GLOBE NEWSWIRE) -- • Publication in International Archives of Allergy and Immunology shows rapid onset and long duration of Bentrio's protective effects in allergic rhinitis sufferers • Mean increase of total nasal symptom score (TNSS) 1.1 points lower vs. no protection, providing clinically meaningful improvement • Mean increase of TNSS 0.4 points lower vs. established powder allergy blocker spray; Bentrio efficacy rated 2x more favorably by patients • Treatment safe and well tolerated

Data Published in Peer-Reviewed Journal Demonstrate Protective Effects of Altamira's Bentrio under Controlled Grass Pollen Exposure

HAMILTON, BERMUDA , Oct. 24, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that its Board of Directors has approved a reverse stock split of its common shares at a ratio of 1-for-20. The reverse stock split is expected to become effective at market opening on October 25, 2022, and the shares to begin trading on the split-adjusted basis on the Nasdaq Capital Market under the Company's existing trading symbol "CYTO." The new CUSIP number following the reverse stock split will be G0360L209. The reverse stock split is primarily being effected to regain compliance with the $1.00 minimum bid price requirement for continued listing on NASDAQ.

Altamira Therapeutics Announces Reverse Stock Split

Adamis Pharmaceuticals

AnPac Bio-Medical Science Co

Borqs Technologies

Clever Leaves Holdings Inc

Cosmos Holdings

Corbus Pharmaceuticals Holdings

Matinas BioPharma Hlds

Nutex Health Inc

Oblong

Penny stocks to watch under $1 right now. The post 10 Top Penny Stocks To Buy For Uner $1 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Top Penny Stocks To Buy For Uner $1 Right Now

Apparently, biotechnology firm Altamira Therapeutics (NASDAQ: CYTO ) would prefer to concentrate on its RNA delivery business. So, the company is divesting its subsidiary that focuses on inner-ear development.

Why Is Altamira Therapeutics (CYTO) Stock Up 70% Today?

HAMILTON, BERMUDA , Oct. 21, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it has entered into an agreement regarding the sale of certain of its legacy assets comprised of its inner ear therapeutics research and development programs and a license to use its RNA delivery technology in certain inner ear applications to a European family office (the “Buyer”), in a multi-step process.

Altamira Therapeutics Announces Divestiture of Inner Ear Development Assets

HAMILTON, BERMUDA , Oct. 13, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it will participate in-person at the RNA Leaders USA Congress being held on October 18-19, 2022 at The Colonnade Hotel in Boston, Massachusetts.

Altamira Therapeutics to Participate at RNA Leaders USA Congress

HAMILTON, BERMUDA , Oct. 03, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that its “NASAR” clinical trial with its BentrioTM nasal spray for seasonal allergic rhinitis (SAR) has resumed the enrollment of study participants in Australia as its pollen season is starting up again.

Altamira Therapeutics Continue Bentrio Clinical Trial for Seasonal Allergic Rhinitis in Australia

HAMILTON, BERMUDA , Sept. 27, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that its Bentrio nasal spray will be re-launched in Europe, initially in Germany, beginning in early October of 2022.

Altamira Therapeutics Re-launches Bentrio in Europe for Allergic Rhinitis

HAMILTON, BERMUDA , Sept. 13, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it has reached its extended enrollment target of 160  confirmed subjects in its COVAMID clinical investigation to evaluate the safety, tolerability, and efficacy of its Bentrio™ nasal spray in patients with acute COVID-19.

Altamira Therapeutics Completes Enrollment for COVAMID Trial with Bentrio in Acute COVID-19

HAMILTON, Bermuda, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced it will hold a call to address questions from investors and discuss the Company's strategy to become the premier provider of RNA therapeutics.

Altamira Therapeutics to Host Investor Call on September 14th

HAMILTON, BERMUDA , Sept. 08, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it will participate in-person at the 4th Annual RAS-Targeted Drug Development Summit being held on September 26-28, 2022 in Boston, Massachusetts.

Altamira Therapeutics to Participate in the 4th Annual RAS-Targeted Drug Development Summit

HAMILTON, BERMUDA , Aug. 03, 2022 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA -- August 3, 2022 -- Altamira Therapeutics ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that its Founder, Chairman and Chief Executive Officer, Thomas Meyer, participated in a video interview with Proactive Investors to discuss the Company's corporate strategy and its key advantages, catalysts, and market opportunities as it advances towards becoming an RNA therapeutics pure play. Mr. Meyer also discussed the planned divestiture or spin-off of its legacy businesses.

Altamira Therapeutics' CEO Interviewed by Proactive Investors to Discuss its Pipeline of RNA Therapeutics and Ongoing Strategic Transformation

HAMILTON, BERMUDA , Aug. 01, 2022 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA / August 1, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it has completed the pre-specified blinded interim sample size analysis in the COVAMID trial to evaluate its Bentrio nasal spray in patients with acute COVID-19. The Company has resumed enrollment to increase the size of the study population from the current 136 to a total of 160 subjects.

Altamira Therapeutics Completes Interim Sample Size Analysis of COVAMID Trial with Bentrio in Acute COVID-19

•Independent peer-reviewed study confirms high potential for OligoPhoreTM delivery platform in RNA-based treatments for osteoarthritis •Knock down of JMJD3 gene remarkably mitigated severity of joint degeneration in animal model •Independent peer-reviewed study confirms high potential for OligoPhoreTM delivery platform in RNA-based treatments for osteoarthritis •Knock down of JMJD3 gene remarkably mitigated severity of joint degeneration in animal model

Altamira Therapeutics' Delivery Platform with siRNA Shown to be Effective Treatment for Osteoarthritis as Published in Peer-Reviewed Journal

•Company's novel drug development program AM-411 builds on positive animal data •Treatments for rheumatoid arthritis represent the second largest therapeutic area globally •AM-411 to run concurrently with AM-401 (KRAS-driven cancers) to leverage platform data •Company's novel drug development program AM-411 builds on positive animal data •Treatments for rheumatoid arthritis represent the second largest therapeutic area globally •AM-411 to run concurrently with AM-401 (KRAS-driven cancers) to leverage platform data

Altamira Therapeutics to Develop Novel Generation of Rheumatoid Arthritis Therapeutics Based on its Proprietary OligoPhore Delivery Platform and siRNA Targeting Key Inflammation Checkpoint

Peer-reviewed study highlights high potential for cell-penetrating peptides in mRNA-based cancer treatments

Altamira Therapeutic's SemaPhore Platform Shown Particularly Effective in Intracellular mRNA Delivery for Cancer Therapy

Study results appeared in "Biomaterials Advances", a highly respected peer-reviewed journal, showcasing growing medical recognition of Company's patented RNA delivery platform for extrahepatic targets. Company's RNA delivery platform demonstrated effectiveness in mitigating abdominal aortic aneurysm progression and rupture in murine model.

Altamira Therapeutic's RNA Delivery Platform Shown to be an Effective Treatment for Abdominal Aortic Aneurysm as Published in Peer-Reviewed Journal

Two Additional Distributors Further Expand Company's Growing Global Footprint To Offer Its Bentrio Nasal Spray for Protection Against Airborne Allergens and Viruses HAMILTON, BERMUDA / ACCESSWIRE / June 29, 2022 / Altamira Therapeutics Ltd. ("the Company") (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it has entered into marketing and distribution agreements in Pakistan and Egypt (the "Agreements") for Bentrio™, its nasal spray for protection against airborne viruses and allergens.

Altamira Therapeutics Secures Marketing & Distribution Agreements To Expand Sales Channels of Bentrio into Egypt and Pakistan

Company gains access to the world's largest OTC market for consumer health products Expects substantial and growing US Bentrio revenue contribution over next couple of years HAMILTON, BERMUDA / ACCESSWIRE / June 27, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that the Company's US subsidiary has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its nasal spray Bentrio™ ("Bentrio Allergy Blocker") for the treatment of allergic rhinitis (hay fever).

Altamira Therapeutics Receives FDA 510(k) Clearance for Bentrio to Treat Allergic Rhinitis

Reached targeted clinical trial enrollment of 136 subjects ahead of schedule At current patient enrollment, top-line data read-out is expected in Q3-22 HAMILTON, BERMUDA / ACCESSWIRE / June 23, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it has reached its targeted enrollment of 136 confirmed subjects in its COVAMID clinical investigation to evaluate the safety, tolerability, and efficacy of its Bentrio™ nasal spray in patients with acute COVID-19.

Altamira Therapeutics Achieves COVAMID Trial Target Enrollment for Bentrio in Acute COVID-19

Significant improvement in balance after four-week treatment with AM-125 20 mg nasal spray vs. placebo Study provides proof-of-concept for enhancement and acceleration of vestibular recovery Treatment well-tolerated by study participants and safe Company plans a US FDA IND filing, and to partner AM-125 Altamira sees opportunity to provide novel treatment option with vestibular stimulant in therapeutic area neglected for decades HAMILTON, BERMUDA / ACCESSWIRE / June 13, 2022 / Altamira Therapeutics Ltd.

News for Altamira Therapeutics Ltd Stock (CYTO)